All News
"In patients with IBD, don't treat with drugs that don't work in IBD." @alexisogdie on why common sense should prevail @rheumnow #RNL2024
TheDaoIndex KDAO2011 ( View Tweet)
How to define "severe" disease? Erosions, multi-site involvement, affecting ADLs/QoL - @AlexisOgdie @rheumnow #RNL2024 https://t.co/gc8bSeSTyJ
TheDaoIndex KDAO2011 ( View Tweet)
2018 ACR/National Psoarasis Foundation Guidelines for Treatment of PsA
- Created helpful definitions of Severe PsA and Severe PsO
#RNL2024 @RheumNow @AlexisOgdie https://t.co/kH4UzlEWxA
Eric Dein ericdeinmd ( View Tweet)
Clinical pearl alert!
Check out https://t.co/rvkKlJ8mtk.
This site can help you with your PsO decision tree and will be updated again this year.
@AlexisOgdie also shares her personal decision tree when approaching patient care while emphasizing shared decision making.
#RNL2024… https://t.co/GFYjHw2hgF https://t.co/I8xpekFmYk
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
“TNFi, IL17i, JAKi--- note that these are the only classes of drug that work for axial spondyloarthritis!” – Dr.
@AlexisOgdie noted ustekinumab, apremilast, and abatacept do not work for inflammatory back pain.
@rheumnow #RLN2024 https://t.co/BHV6qCUdYi
TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow
@AlexisOgdie
Many therapies for SpA - but ONLY TNFi, IL17i, and JAKi for AxSpA
Check out https://t.co/V7JGc6t72C to help guide treatment decisions: Prior therapies? enthesitis? concomitant IBD/uveitis? comorbidities? Pt preferences? https://t.co/hfFikMs9YL
Links:
Eric Dein ericdeinmd ( View Tweet)
Thinking of joint, skin, axial disease in psoriatic arthritis and extra-articular manifestations leading to shared decision making, Alexis Ogdie #RNL2024 @RheumNow https://t.co/F57sEicht7
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Evolution of treatment landscape in PsA by @AlexisOgdie @RheumNow #RNL2024 https://t.co/ut1e5Z2CjK
Richard Conway RichardPAConway ( View Tweet)
Cognitive framework for selecting therapy in PsA by @AlexisOgdie @RheumNow #RNL2024 https://t.co/ZepkyA0mWj
Richard Conway RichardPAConway ( View Tweet)
@AlexisOgdie discusses the current and expected future SpA therapeutic options.
However, and I also discuss this with my patients, we are more limited in AxSpA vs PsA (with axial disease.)
#RNL2024 @RheumNow https://t.co/dlVgWblSXy
Dr. Rachel Tate uptoTate ( View Tweet)
Importance of focusing on patient goals in psoriatic arthritis, use shared decision making and apply the clinical guidelines and treatment options within this context, Alexis Ogdie #RNL2024 @RheumNow https://t.co/jCFWUqJNn3
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Functional outcomes of immune aging.
Connie Weyand.
#RNL2024
@RheumNow https://t.co/ZLL7N30n13
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Clinical implications of immune aging.
Connie Weyand.
#RNL2024
@RheumNow https://t.co/QUbvkIvPco
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Stressed ER is a major TNF producer.
Connie Weyand.
#RNL2024
@RheumNow https://t.co/zsSD8XWFcP
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Consequence of aged immune system.
Connie Weyand.
#RNL2024
@RheumNow https://t.co/gfCTfzulR9
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Remission in gout is 6 to 12 months with no flares.
Lisa Stamp.
#RNL2024
@RheumNow https://t.co/OlJK7HMNeX
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. @AlexisOgdie describes her decision tree when assessing SpA/PsA patients. #Rheumtwitter What do you do?
#RNL2024 @RheumNow https://t.co/T4ZRKDplqe
Dr. Rachel Tate uptoTate ( View Tweet)
Role of anti- inflammatory prophylaxis when starting ULT in gout .
6 months. ? Longer period of prophylaxis or no prophylaxis?
Lisa Stamp
#RNL2024
@RheumNow https://t.co/sKKHWp9Ihw
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Serum urate level and gout flare.
DECT images at baseline and target.
Lisa Stamp.
#RNL2024
@RheumNow https://t.co/z2PuoHnH2T
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
How/when to choose biologics in pts with active psoriasis from Dr April Armstrong #rnl2024
Dr. John Cush RheumNow ( View Tweet)